Newly Granted European Patent Protects VBL Therapeutics’ Anti-MOSPD2 Antibodies for Inflammation Until at least July 2036

NEXT STORY
Revolution Medicines to Present Interim Data at ENA 2020 from Phase 1b/2 Clinical Trial Combining RMC-4630 with Cobimetinib for RAS-Addicted Solid Tumors
PREV STORY
Avenue Therapeutics Receives Complete Response Letter from the FDA for IV Tramadol
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Takeda and Frazier Healthcare Partners Announce Collaboration to Launch HilleVax, Inc. to Develop Clinical Stage Norovirus Vaccine Candidate

author_avatar
NASDAQ Market News

U.S. FDA Grants PAVmed Subsidiary, Lucid Diagnostics, Breakthrough Device Designation for its EsoGuard Esophageal DNA Test

author_avatar
NASDAQ Market News

Immunocore Announces Start of Phase I ImmTAC® Study in Patients with Solid Tumours

PRESS RELEASE Immunocore Announces Start of Phase I ImmTAC® Study in Patients with Solid ...

author_avatar
NASDAQ Market News